CoChat

New/emerging psychoactive substances and associated psychopathological consequences

Open access

The DOI matches its Crossref record; 125 of the 126 references it cites were found in a registry or an index.

Abstract

Background: The present paper provides an updated review of both the large number of new/novel/emerging psychoactive substances (NPS) and their associated psychopathological consequences. Focus was here given on identification of those NPS being commented in specialised online sources and the related short-/long-term psychopathological and medical ill-health effects. Methods: NPS have been identified through an innovative crawling/navigating software, called the ‘NPS.Finder®’, created in order to facilitate the process of early recognition of NPS online. A range of information regarding NPS, including chemical and street names; chemical formula; three-dimensional image and anecdotally reported clinical/psychoactive effects, were here made available. Results: Using the ‘NPS.Finder®’ approach, a few thousand NPS were here preliminarily identified, a number which is about 4-fold higher than those figures suggested by European and international drug agencies. NPS most commonly associated with the onset of psychopathological consequences included here synthetic cannabinoids/cannabimimetics; new synthetic opioids; ketamine-like dissociatives; novel stimulants; novel psychedelics and several prescription and over-the-counter medicines. Conclusions: The ever-increasing changes in terms of recreational psychotropics' availability represent a relatively new challenge for psychiatry, as the pharmacodynamics and pharmacokinetics of many NPS have not been thoroughly understood. Health/mental health professionals should be informed about the range of NPS; their intake modalities; their psychoactive sought-after effects; the idiosyncratic psychotropics' combinations and finally, their medical and psychopathological risks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0033291719001727

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 12

  1. UNODC (2018). Analysis of drug markets: opiates, cocaine, cannabis, synthetic drugs. Vienna: UNODC. Available from: http://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_3_DRUG_MARKET S.pdf (accessed on October 21,2018).
  2. Lovrecic, B. and Lovrecic, M. (2017). Novel psychoactive synthetic cannabinoids and synthetic cathinones: the never-ending story of potential clinical toxicity. Heroin Addiction and Related Clinical Problems. Available from: https://www.researchgate.net/profile/Barbara_Lovrecic/publication/319554544
  3. Cheng, S., Yeo, J., Brown, E., Regan, A. (2012). Bath Salts and Synthetic Cannabinoids: A Review. American Academy of Emergency Medicine 19, 19-22.
  4. UNODC (2018). World Drug Report 2018 Volume 3 -Analysis of drug markets: opiates, cocaine, cannabis, synthetic drugs. Vienna: United Nations Office on Drugs and Crime. Available from: https://www.unodc.org/wdr2018/ (accessed on November 23, 2018).
  5. UNODC (2013). The challenge of new psychoactive substances: A Report from the Global SMART Programme. Vienna: United Nations Office on Drugs and Crime. Available from: https://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf (accessed on November 23, 2018).
  6. Denysenko, L., Freudenreich, O., Philbrick, K., Penders, T., Zimbrean, P., Nejad, S., Chwastiak, L., Dickerman, A., Niazi, S., Shim, J., Soellner, W. (2015). Catatonia in Medically Ill Patients An Evidence-Based Medicine (EBM) Monograph for Psychosomatic Medicine Practice. The European Association of Psychosomatic Medicine 30, 140-155.
  7. Chatwin, C., Measham, F., O'Brien, K., Sumnall, H. (2017). New Psychoactive Substances and Human Enhancement Drugs. International Journal of Drug Policy 40, 1-5.
  8. Brennan, B.P., Kanayama, G., Pope, H.G. Jr (2013). Performance-enhancing drugs on the web: a growing public-health issue. The American Journal of Addiction 22, 158-61.
  9. Brennan, R., Wells, J.S.G., Van Hout, M.C. (2017). The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review. Health and Social Care in the Community 25, 1459-1531.
  10. Callaghan Iii, D.J. (2018). A glimpse into the underground market of melanotan. Dermatology Online Journal 24(5). pii: 13030/qt2gz9f9jk.
  11. Santos, G.H. and Coomber, R. (2017). The risk environment of anabolic- androgenic steroid users in the UK: Examining motivations, practices and accounts of use. International Journal of Drug Policy Volume 40, 35-43.
  12. 2017, High Risk Drug use and New Psychoactive Substances. EMCDDA Rapid Communication

Cited by

See all 133

Metadata

Authors
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A.
Affiliations
  • University of Hertfordshire (GB)
  • Homerton University Hospital (GB)
  • Swansea University (GB)
  • Camden and Islington NHS Foundation Trust (GB)
  • ASL Roma (IT)
  • University of Duisburg-Essen (DE)
  • Marconi University (IT)
Corresponding author
Chiappini, S.
Venue
Psychological Medicine
Published
2019-07-22
Volume
51
Issue
1
Pages
30-42
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W2957505335
Cited by
119
References
126
Citations by year
2026: 11 · 2025: 20 · 2024: 18 · 2023: 14 · 2022: 15 · 2021: 22 · 2020: 14 · 2019: 4
FWCI
2.53
Type
journal article
Language
en
Open access
Locations
  • Psychological Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • University of Hertfordshire Research Archive (University of Hertfordshire) (acceptedVersion)
  • University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
new psychoactive substances, synthetic cannabinoids, synthetic opioids, prescription drug misuse, psychopathological consequences, recreational drug use, mental health risk
MeSH terms
Recreational Drug Use, Humans, Psychopathology, Psychotropic Drugs, Illicit Drugs, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.